SCHEMBL2867919

SCHEMBL2867919

O=C1OC(c2ccccc2)(c2ccccc2)C2CNCCCN12

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.46
ADRB2 P07550 1/20 0.42
APLNR P35414 1/20 0.42
GLP1R P43220 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
GPR119 Q8TDV5 1/20 0.42
HTR2C P28335 8/20 0.36
HTR2B P41595 8/20 0.36
HTR2A P28223 4/20 0.36
CHRM2 P08172 1/20 0.35
CHRM3 P20309 1/20 0.35
CNR2 P34972 1/20 0.33
GRIN1 Q05586 2/20 0.33
GRIN2A Q12879 2/20 0.33
GRIN2B Q13224 1/20 0.33
HSD11B1 P28845 1/20 0.33
KCNN4 O15554 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856594 0.92 NPSR1 (0.47) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL23052957 0.81 NPSR1 (0.50) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2859274 0.78 HTR2C (0.40) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2858341 0.78 NPSR1 (0.44) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2868956 0.77 KCNN4 (0.40) NPSR1ADRB2APLNRGLP1RFFAR4
Hydrochloric Acid SCHEMBL2868925 0.71 NPSR1 (0.60) NPSR1ADRB2APLNRGLP1RFFAR4
Hydrochloric Acid SCHEMBL2865785 0.69 NPSR1 (0.58) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2858342 0.69 SLC6A2 (0.44) NPSR1HTR2CHTR2BHTR2ACHRM2
SCHEMBL2861967 0.69 NPSR1 (0.54) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2866025 0.68 NPSR1 (0.60) NPSR1ADRB2APLNRGLP1RFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 NPSR1 211/4885ADRB2 449/4885APLNR 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.